DE2636599C2 - N-Acylsaccharine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel - Google Patents

N-Acylsaccharine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Info

Publication number
DE2636599C2
DE2636599C2 DE2636599A DE2636599A DE2636599C2 DE 2636599 C2 DE2636599 C2 DE 2636599C2 DE 2636599 A DE2636599 A DE 2636599A DE 2636599 A DE2636599 A DE 2636599A DE 2636599 C2 DE2636599 C2 DE 2636599C2
Authority
DE
Germany
Prior art keywords
saccharin
furoyl
elastase
emphysema
aerosol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE2636599A
Other languages
German (de)
English (en)
Other versions
DE2636599A1 (de
Inventor
Howard Holmdel N.J. Jones
Dennis Milford N.J. Mulvey
Morris Watchung N.J. Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE2636599A1 publication Critical patent/DE2636599A1/de
Application granted granted Critical
Publication of DE2636599C2 publication Critical patent/DE2636599C2/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE2636599A 1975-08-20 1976-08-13 N-Acylsaccharine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel Expired DE2636599C2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/606,271 US4195023A (en) 1975-08-20 1975-08-20 2-(2-Furoyl)1,2-benzisothiazole-3-one, 2-(2-furoyl) saccharin, and 2-(2-thenoyl) saccharin

Publications (2)

Publication Number Publication Date
DE2636599A1 DE2636599A1 (de) 1977-03-03
DE2636599C2 true DE2636599C2 (de) 1985-10-24

Family

ID=24427291

Family Applications (1)

Application Number Title Priority Date Filing Date
DE2636599A Expired DE2636599C2 (de) 1975-08-20 1976-08-13 N-Acylsaccharine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel

Country Status (9)

Country Link
US (1) US4195023A (enExample)
JP (1) JPS5225769A (enExample)
CH (2) CH627461A5 (enExample)
DE (1) DE2636599C2 (enExample)
DK (1) DK352176A (enExample)
FR (1) FR2321288A1 (enExample)
GB (1) GB1518404A (enExample)
NL (1) NL7608676A (enExample)
SE (1) SE434946B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4276298A (en) * 1978-03-24 1981-06-30 Merck & Co., Inc. 2-Aryl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors
US4369183A (en) 1979-09-06 1983-01-18 Merck & Co., Inc. 2-Pyridyl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors
US4315861A (en) * 1979-11-08 1982-02-16 Chinoin Gyogyszer RT Process for O-acylating phenol derivatives and acylating compositions for this purpose
US4323469A (en) * 1980-10-28 1982-04-06 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Process for O-acylating phenol derivatives and acylating compositions for this purpose
US5380737A (en) * 1989-05-04 1995-01-10 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
NZ233521A (en) * 1989-05-04 1992-05-26 Sterling Drug Inc 2-substituted saccharin derivatives, preparation and pharmaceutical compositions thereof
FR2659327A1 (fr) * 1990-03-08 1991-09-13 Centre Nat Rech Scient Derives du benzisothiazolinone-1-dioxyde, utilisables comme inhibiteurs des elastases.
US5306818A (en) * 1990-11-01 1994-04-26 Sterling Winthrop Inc. Tetrahydro 2-saccharinylmerthyl aryl carboxylates
US5512589A (en) * 1990-11-01 1996-04-30 Sterling Winthrop Inc. 2-saccharinylmethyl aryl carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
AU668694B2 (en) * 1991-12-19 1996-05-16 Sanofi-Synthelabo Saccharin derivative proteolytic enzyme inhibitors
US5378720A (en) * 1991-12-19 1995-01-03 Sterling Winthrop Inc. Saccharin derivative proteolytic enzyme inhibitors
US5296496A (en) * 1991-12-27 1994-03-22 Sterling Winthrop Inc. 2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
US5187173A (en) * 1991-12-27 1993-02-16 Sterling Winthrop Inc. 2-saccharinylmethyl and 4,5,6,7-tetrahydro-2-saccharinylmethyl phosphates, phosphonates and phosphinates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
TW226016B (enExample) * 1991-12-30 1994-07-01 Sterling Winthrop Inc
AU653279B2 (en) * 1991-12-30 1994-09-22 Sanofi Novel 2-saccharinylmethyl heterocyclic carboxylates useful as proteolytic enzyme inhibitors and compositions and method of use thereof
GB9626570D0 (en) * 1996-12-20 1997-02-05 Zeneca Ltd Process for making benzisothiazolin-3-ones
US5994396A (en) * 1997-08-18 1999-11-30 Centaur Pharmaceuticals, Inc. Furansulfonic acid derivatives and pharmaceutical compositions containing the same
US7361767B2 (en) * 2003-11-14 2008-04-22 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
US7943388B2 (en) * 2003-11-14 2011-05-17 3M Innovative Properties Company Acoustic sensors and methods
US7423155B2 (en) * 2003-11-14 2008-09-09 3M Innovative Properties Company N-sulfonyldicarboximide containing tethering compounds
US7169933B2 (en) * 2003-11-14 2007-01-30 3M Innovative Properties Company N-sulfonylaminocarbonyl containing compounds
US7544754B2 (en) 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
US7544756B2 (en) * 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
CN113200937B (zh) * 2021-05-14 2022-12-13 郑州大学 一种催化氧化制备1,2-苯并异噻唑啉-3-酮的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1147947B (de) * 1961-07-25 1963-05-02 Knoll Ag Verfahren zur Herstellung neuer 1, 2-Benzisothiazolone
FR1364176A (fr) * 1962-05-18 1964-06-19 Montedison Spa Composés fongiciles à usage agricole

Also Published As

Publication number Publication date
NL7608676A (nl) 1977-02-22
DK352176A (da) 1977-02-21
US4195023A (en) 1980-03-25
FR2321288B1 (enExample) 1978-12-22
JPS5225769A (en) 1977-02-25
SE7608748L (sv) 1977-02-21
FR2321288A1 (fr) 1977-03-18
CH627461A5 (de) 1982-01-15
GB1518404A (en) 1978-07-19
SE434946B (sv) 1984-08-27
CH625232A5 (enExample) 1981-09-15
DE2636599A1 (de) 1977-03-03

Similar Documents

Publication Publication Date Title
DE2636599C2 (de) N-Acylsaccharine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE69019111T2 (de) Ascorbinsäure-Tocopheryl-Phosphatdiester zur Hemmung der Maillard-Reaktion.
DE3402628C2 (enExample)
DE60026826T2 (de) Alterungsschutztetrapeptid, dieses enthaltende pharmazeutische zusammensetzungen und seine verwendung
DE69822665T2 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE68924439T2 (de) Substituierte Azetidinone als entzündungshemmende und antidegenerative Wirkstoffe.
DE69006094T2 (de) Pharmazeutische Zusammensetzungen.
DE69113938T2 (de) Zusammensetzungen von Maillard-Reaktion inhibitoren.
DE60022560T2 (de) Mittel zur behandlung der amyotrophischen lateralsklerose (als)
CH640140A5 (de) Verfahren zur herstellung von intravenoes injizierbarem gamma-globulin.
WO2005037257A2 (de) Neue alanyl-aminopeptidasen-inhibitoren zur funktionellen beeinflussung unterschiedlicher zellen und zur behandlung immunologischer, entzündlicher, neuronaler und anderer erkrankungen
DE69016821T2 (de) Behandlungsmittel gegen Osteoarthritis.
DE60116860T2 (de) Zusammensetzungen zur behandlung von schäden verursacht durch ischämie / reperfusion oder oxidativem stress
CH616423A5 (enExample)
DE2923009A1 (de) Mittel zur prophylaxe und behandlung der fibrose
DE60026491T2 (de) Melagatran zur behandlung von entzündungen
DE69804998T2 (de) Mometasonfuroat-suspensionen zum zerstäuben
DE3212882C2 (enExample)
DE69520591T2 (de) Bestimmung von steroid sulfatase
DE10330768A1 (de) Verwendung von aus extremophilen Bakterien gewonnenen Osmolyten zur Herstellung von inhalierbaren Arzneimitteln zur Prophylaxe und Behandlung pulmonaler und kardiovaskulärer Erkrankungen, sowie eines Osmolyte als Wirkstoffbestandteil enthaltende Inhalationsvorrichtung
DE69024060T2 (de) Osteogenesis-stimulierende mittel.
DE10150172A1 (de) Neue Verbindungen, die Protein Tyrosin Phosphatase 1B (PTP-1B) inhibieren
EP1397128B1 (de) Kappa-opiatagonist für die behandlung der reizblase
EP4149433A1 (de) Kompatible solute zur prävention oder behandlung von sars-cov-2-infektionen
DE2411823A1 (de) Verwendung von 1,2,4-triazol-3-carboxamiden und -thiocarboxamiden als antivirenmittel

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8128 New person/name/address of the agent

Representative=s name: ABITZ, W., DIPL.-ING.DR.-ING. MORF, D., DR., PAT.-

D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee